A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer

Inclusion Criteria

• •Subjects voluntarily participated in the trial and signed the informed consent form;
• •Aged ≥ 18 years and \< 80 years, regardless of gender;
• •Stable vital signs;
• •Patients with gastric adenocarcinoma confirmed by gastroscopic biopsy;
• •Tumors judged as unresectable by attending physicians;
• •Receiving anti-PD-1 therapy combined with chemotherapy as first-line treatment;
• •No history of allergic diseases and non-allergic constitution;
• •No history of drug abuse;
• •Non-pregnant and non-lactating females (applicable to male subjects as well);
• •No participation in any drug clinical trial (including investigational drugs of this trial) within 3 months prior to enrollment.
• •Concurrent primary malignant tumors at other sites;
• •Poor general condition, severe infection, respiratory insufficiency, or other conditions leading to inability to cooperate with the trial;
• •Patients with mental disorders, consciousness disturbance, or poor treatment compliance;
• •Suspected or confirmed history of drug abuse;
• •Immunodeficiency, or long-term use of immunosuppressants and glucocorticoids;
• •Pregnant or lactating women;
• •Sponsors, investigators directly involved in this trial, and their immediate family members;
• •Individuals unsuitable for enrollment for any reason as judged by the investigator.